Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)
Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –
Ascendis Pharma A/S free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Ascendis Pharma A/S's free cash flow for the twelve months ending Sep 30, 2024 was -€262.44M. For fiscal 2023 it was -€469.80M. The highest annual figure on record is -€44.51M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -€469.80M | – |
| FY2022 | Dec 31, 2022 | -€510.19M | – |
| FY2021 | Dec 31, 2021 | -€441.35M | – |
| FY2020 | Dec 31, 2020 | -€291.41M | – |
| FY2019 | Dec 31, 2019 | -€181.10M | – |
| FY2018 | Dec 31, 2018 | -€141.45M | – |
| FY2017 | Dec 31, 2017 | -€96.04M | – |
| FY2016 | Dec 31, 2016 | -€60.85M | – |
| FY2015 | Dec 31, 2015 | -€44.51M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -€56.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -€61.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -€101.78M | – |
| Q4 FY2023 | Dec 31, 2023 | -€42.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -€125.70M | – |
| Q2 FY2023 | Jun 30, 2023 | -€153.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -€148.13M | – |
| Q4 FY2022 | Dec 31, 2022 | -€145.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -€102.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -€128.12M | – |
| Q1 FY2022 | Mar 31, 2022 | -€134.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -€128.11M | – |
| Q3 FY2021 | Sep 30, 2021 | -€108.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -€118.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -€85.64M | – |
| Q4 FY2020 | Dec 31, 2020 | -€94.60M | – |
| Q3 FY2020 | Sep 30, 2020 | -€62.69M | – |
| Q2 FY2020 | Jun 30, 2020 | -€61.20M | – |
| Q1 FY2020 | Mar 31, 2020 | -€72.93M | – |
| Q4 FY2019 | Dec 31, 2019 | -€50.37M | – |
| Q3 FY2019 | Sep 30, 2019 | -€61.20M | – |
| Q2 FY2019 | Jun 30, 2019 | -€6.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -€63.33M | – |
| Q4 FY2018 | Dec 31, 2018 | -€36.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -€47.54M | – |
| Q2 FY2018 | Jun 30, 2018 | -€20.45M | – |
| Q1 FY2018 | Mar 31, 2018 | -€36.84M | – |
| Q4 FY2017 | Dec 31, 2017 | -€24.39M | – |
| Q3 FY2017 | Sep 30, 2017 | -€25.90M | – |
| Q2 FY2017 | Jun 30, 2017 | -€24.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -€21.63M | – |
See a number that looks wrong?